Voya Investment Management LLC Sells 255,297 Shares of Adaptive Biotechnologies Corporation $ADPT

Voya Investment Management LLC decreased its stake in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 16.4% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,304,609 shares of the company’s stock after selling 255,297 shares during the quarter. Voya Investment Management LLC owned about 0.86% of Adaptive Biotechnologies worth $19,517,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. XTX Topco Ltd bought a new position in Adaptive Biotechnologies during the second quarter valued at $793,000. SG Americas Securities LLC raised its position in shares of Adaptive Biotechnologies by 53.2% during the 2nd quarter. SG Americas Securities LLC now owns 37,328 shares of the company’s stock valued at $435,000 after buying an additional 12,963 shares in the last quarter. Hillsdale Investment Management Inc. purchased a new position in Adaptive Biotechnologies in the second quarter worth about $6,618,000. Diversified Trust Co bought a new stake in Adaptive Biotechnologies during the second quarter worth approximately $438,000. Finally, Intech Investment Management LLC lifted its stake in shares of Adaptive Biotechnologies by 26.0% in the 2nd quarter. Intech Investment Management LLC now owns 72,605 shares of the company’s stock valued at $846,000 after purchasing an additional 14,990 shares during the last quarter. 99.17% of the stock is currently owned by institutional investors.

Adaptive Biotechnologies Price Performance

ADPT opened at $17.00 on Monday. The business has a fifty day moving average price of $16.58 and a 200 day moving average price of $13.70. Adaptive Biotechnologies Corporation has a 12 month low of $5.84 and a 12 month high of $20.76. The stock has a market capitalization of $2.60 billion, a price-to-earnings ratio of -31.48 and a beta of 2.20.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.01. Adaptive Biotechnologies had a negative return on equity of 58.40% and a negative net margin of 31.50%.The business had revenue of $93.97 million during the quarter, compared to analysts’ expectations of $58.76 million. During the same quarter last year, the business posted ($0.22) EPS. The business’s quarterly revenue was up 102.4% compared to the same quarter last year. On average, research analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Francis Lo sold 113,890 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $15.57, for a total transaction of $1,773,267.30. Following the completion of the sale, the insider owned 315,978 shares in the company, valued at $4,919,777.46. The trade was a 26.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Harlan S. Robins sold 10,000 shares of the stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $16.61, for a total transaction of $166,100.00. Following the completion of the transaction, the insider owned 1,232,312 shares in the company, valued at $20,468,702.32. This represents a 0.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 1,216,133 shares of company stock valued at $20,882,134 over the last 90 days. 6.40% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Guggenheim assumed coverage on shares of Adaptive Biotechnologies in a research note on Tuesday, September 30th. They issued a “buy” rating and a $20.00 price target on the stock. Morgan Stanley initiated coverage on shares of Adaptive Biotechnologies in a research note on Monday, December 1st. They set an “equal weight” rating and a $21.00 target price on the stock. BTIG Research boosted their price target on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Piper Sandler upped their price objective on shares of Adaptive Biotechnologies from $15.00 to $20.00 and gave the stock an “overweight” rating in a report on Wednesday, October 15th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Wednesday, October 8th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $17.11.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.